Inbiomotion, a CataloniaBio &HealthTech member, is developing a unique single-gene-based biomarker for the personalized adjuvant treatment of early-stage (stage I-III) breast cancer patients. They recently announced the publication of the resultsof the prospectively-planned, retrospective analysis of clinical outcome data from a new clinical study in Journal of the National Cancer Institute, Cancer Spectrum. The data show that in patients with MAF-negative tumors (determined with Inbiomotion’s proprietary MAF Test®), adjuvant treatment with clodronate was associated with a significant benefit in overall survival compared to placebo-treated control patients receiving the same standard of care.
Results confirm the company’s previous data (AZURE trial analyses) on its proprietary MAF Test® published in Lancet Oncology in 2018. “This study confirms our previous findings and the clinical utility ofMAF Test® as a unique tool for precision medicine in early breast cancer. Over700,000 early-stage breast cancer patients in Europe and US are diagnosed everyyear and improving their treatment options through precision medicine is an important goal”, said Joël Jean-Mairet, Executive Chairman of the Board of Inbiomotion. “The data indicate that around 15,000 lives could be saved annually in Europe and US”.
Inbiomotion SL, a spin-off of IRB Barcelona and the Catalan Institution for Research and Advanced Studies (ICREA), founded by Prof. Roger Gomis, is developing a unique single gene-based biomarker for the personalized adjuvant treatment of early-stage breast cancer patients. The biomarker has been technically and analytically validated. The company is partly participated by Ysios Capital.
Photo: Roger Gomis and Joël Jean-Mairet
Comments